As of Nov 19, 2026, 2 of 2 active firms rate TNXP a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
TNXP EPS & revenue forecast
EPS · NEXT QUARTER
$-2.42
Range $-2.42 – $-2.42 · 1 analysts · -17% YoY
Next period, 1 analysts expect Tonix Pharmaceuticals Holding Corp to earn $-2.42 a share (range $-2.42 – $-2.42), versus $-2.93 a year earlier. Full-year consensus is $-10.91, growing to $-7.00 the year after.
REVENUE · NEXT QUARTER
$23.3M
Range $17.5M – $29.0M · 1 analysts · +238% YoY
Revenue is expected to reach $23.3M (range $17.5M – $29.0M), +238.0% year-over-year. Full-year consensus is $57.5M, rising to $112.8M next year.
Top analysts covering Tonix Pharmaceuticals Holding Corp
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on TNXP.
#1
TF
Tiago Fauth
Raymond James
Buy
$26.00+825.3% to target
Coverage
—
+ Follow
#2
SK
Stacy Ku
TD Cowen
Buy
$22.00+682.9% to target
Coverage
—
+ Follow
#3
RL
Robert LeBoyer
Noble Financial
Buy
$37.00+1216.7% to target
Coverage
—
+ Follow
TNXP stock forecast FAQ
What is TNXP's average 12-month price target?+
The 2 active firms with a live target average $24.00 for Tonix Pharmaceuticals Holding Corp over the next 12 months, ranging from a $26.00 high to a $22.00 low, as of Nov 19, 2026.
Is TNXP stock a Buy, Sell or Neutral right now?+
The current consensus is Insufficient coverage. Of the 2 active firms as of Nov 19, 2026, 2 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for TNXP?+
The Street-high target is $26.00 (Raymond James), and the Street-low is $22.00 (TD Cowen). The average of all 2 active-firm targets is $24.00.
How many active Wall Street firms cover TNXP?+
2 active firms have a recognized rating on Tonix Pharmaceuticals Holding Corp as of Nov 19, 2026, and 2 active firms carry a live 12-month price target.
Who is the most accurate analyst covering TNXP?+
Among analysts who currently cover TNXP, Tiago Fauth of Raymond James has the strongest overall Quantellect track record. Their current call is Buy with a $26.00 target.
What is Tonix Pharmaceuticals Holding Corp's projected EPS for next quarter?+
The consensus estimate is $-2.42 per share (range $-2.42 – $-2.42) across 1 analysts. Full-year EPS is projected at $-10.91, rising to $-7.00 the following year.
How much revenue is Tonix Pharmaceuticals Holding Corp expected to report next quarter?+
Consensus revenue is $23.3M (range $17.5M – $29.0M). Full-year revenue is projected at $57.5M, growing to $112.8M next year.
Have analysts been upgrading or downgrading TNXP lately?+
As of Nov 19, 2026, 2 of 2 active firms rate TNXP a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their TNXP calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.